Literature DB >> 11038166

Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin.

W Jacobsen1, B Kuhn, A Soldner, G Kirchner, K F Sewing, P A Kollman, L Z Benet, U Christians.   

Abstract

In an in vitro study, we compared the cytochrome P450 (CYP)-dependent metabolism and drug interactions of the acid and lactone forms of the 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitor atorvastatin. Metabolism of atorvastatin acid and lactone by human liver microsomes resulted in para-hydroxy and ortho-hydroxy metabolites. Both substrates were metabolized mainly by CYP3A4 and CYP3A5. Atorvastatin lactone had a significantly higher affinity to CYP3A4 than the acid (K(m): para-hydroxy atorvastatin, 25.6 +/- 5.0 microM; para-hydroxy atorvastatin lactone, 1.4 +/- 0.2 microM; ortho-hydroxy atorvastatin, 29.7 +/- 9.4 microM; and ortho-hydroxy atorvastatin lactone, 3.9 +/- 0.2 microM). Compared with atorvastatin acid, CYP-dependent metabolism of atorvastatin lactone to its para-hydroxy metabolite was 83-fold higher [formation CL(int) (V(max)/K(m)): lactone 2949 +/- 3511 versus acid 35.5 +/- 48.1 microl. min(-1). mg(-1)] and to its ortho-hydroxy metabolite was 20-fold higher (CL(int): lactone 923 +/- 965 versus acid 45.8 +/- 59. 1 microl. min(-1). mg(-1)). Atorvastatin lactone inhibited the metabolism of atorvastatin acid by human liver microsomes with an inhibition constant (K(i)) of 0.9 microM while the K(i) for inhibition of atorvastatin by atorvastatin lactone was 90 microM. Binding free energy calculations of atorvastatin acid and atorvastatin lactone complexed with CYP3A4 revealed that the smaller desolvation energy of the neutral lactone compared with the anionic acid is the dominant contribution to the higher binding affinity of the lactone rather than an entropy advantage. Because atorvastatin lactone has a significantly higher metabolic clearance and the lactone is a strong inhibitor of atorvastatin acid metabolism, it can be expected that metabolism of the lactone is the relevant pathway for atorvastatin elimination and drug interactions. We hypothesize that most of the open acid metabolites present in human plasma are generated by interconversion of lactone metabolites.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11038166

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  62 in total

Review 1.  Old and new molecular mechanisms associated with platelet resistance to antithrombotics.

Authors:  Antonio J López Farré; Juan Tamargo; Petra J Mateos-Cáceres; Luís Azcona; Carlos Macaya
Journal:  Pharm Res       Date:  2010-07-14       Impact factor: 4.200

2.  Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin.

Authors:  Jaekyu Shin; Daniel F Pauly; Michael A Pacanowski; Taimour Langaee; Reginald F Frye; Julie A Johnson
Journal:  Pharmacotherapy       Date:  2011-10       Impact factor: 4.705

3.  Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes.

Authors:  Miroslav Dostalek; Wai-Johnn Sam; Komal R Paryani; Joyce S Macwan; Reginald Y Gohh; Fatemeh Akhlaghi
Journal:  Clin Pharmacokinet       Date:  2012-09-01       Impact factor: 6.447

4.  Atorvastatin metabolite measurements as a diagnostic tool for statin-induced myopathy.

Authors:  Ine B Skottheim; Martin P Bogsrud; Monica Hermann; Kjetil Retterstøl; Anders Åsberg
Journal:  Mol Diagn Ther       Date:  2011-08-01       Impact factor: 4.074

5.  CYP isoform specificity toward drug metabolism: analysis using common feature hypothesis.

Authors:  M Ramesh; Prasad V Bharatam
Journal:  J Mol Model       Date:  2011-05-12       Impact factor: 1.810

Review 6.  Predicting drug metabolism: experiment and/or computation?

Authors:  Johannes Kirchmair; Andreas H Göller; Dieter Lang; Jens Kunze; Bernard Testa; Ian D Wilson; Robert C Glen; Gisbert Schneider
Journal:  Nat Rev Drug Discov       Date:  2015-04-24       Impact factor: 84.694

7.  UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone.

Authors:  Camilla Stormo; Martin P Bogsrud; Monica Hermann; Anders Åsberg; Armin P Piehler; Kjetil Retterstøl; Marianne K Kringen
Journal:  Mol Diagn Ther       Date:  2013-08       Impact factor: 4.074

8.  Thyroid hormone beta receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys.

Authors:  B R Ito; B-H Zhang; E E Cable; X Song; J M Fujitaki; D A MacKenna; C E Wilker; B Chi; P D van Poelje; D L Linemeyer; M D Erion
Journal:  Br J Pharmacol       Date:  2009-01-22       Impact factor: 8.739

9.  Pharmacokinetic evaluation of the interaction between hepatitis C virus protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatin.

Authors:  E G J Hulskotte; H-P Feng; F Xuan; S Gupta; M G J A van Zutven; E O'Mara; J A Wagner; J R Butterton
Journal:  Antimicrob Agents Chemother       Date:  2013-03-25       Impact factor: 5.191

10.  Vitamin d levels and lipid response to atorvastatin.

Authors:  José Luis Pérez-Castrillón; Laura Abad Manteca; Gemma Vega; Javier Del Pino Montes; Daniel de Luis; Antonio Duenas Laita
Journal:  Int J Endocrinol       Date:  2009-08-19       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.